Microba completes dosing in Phase I IBD Clinical Trial
Microba Life Sciences today announced that all participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba's The...
Advancing health with new solutions developed from the human microbiome
Our platform technologies are driving new solutions for improving human health
“Testing, understanding and modifying the microbiome is key to addressing many diseases and improving our health. Microba’s leading technology is driving this health transformation.”
— Professor Ian Frazer, Chair of Medical Advisory Board
Partner with us
Through partnerships with leading organisations worldwide, we are powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
Speak with our team
Latest news
Read about our progress in exploring the gut microbiome and our latest partnerships to develop new health solutions.
Newsroom
First distribution agreement executed with Sonic Healthcare
Microba Life Sciences has executed a commercial agreement with Sonic Healthcare Limited through a wholly owned subsidiary Douglass Hanly Moir Patho...